Medication info
Lodivica Tablet 2.5/20 mg (Escitalopram Nicotinate, Olmesartan Medoxomil)

Lodivica Tablet 2.5/20 mg (Escitalopram Nicotinate, Olmesartan Medoxomil)

Prescription medicationTabletOral
Ingredient · strength
S-Amlodipine Nicotinate›3.253mg / 1 tabletOlmesartan Medoxomil›20mg / 1 tablet
Manufacturer / importer
Hanlim Pharmaceutical Co., Ltd.
Appearance
White round film-coated tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 201404535 · Approved 2014.09.30 · Insurance code 645305020

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
This medicine is administered as 1 tablet once daily with water, without regard to meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended to adjust the dose using the individual components (S-amlodipine (amlodipine) or olmesartan medoxomil). However, if blood pressure is not adequately controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 5/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into account. The recommended doses are as follows. - 2.5/20 mg: Administer to patients whose blood pressure is not adequately controlled with S-amlodipine 2.5 mg (amlodipine 5 mg) or olmesartan medoxomil 20 mg as monotherapy. - 5/20 mg: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg as monotherapy. - 2.5/40 mg: Administer to patients whose blood pressure is not adequately controlled with 2.5/20 mg. - 5/40 mg: Administer to patients whose blood pressure is not adequately controlled with 2.5/40 mg. ○ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily, and administration of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ○ Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics should be closely monitored for blood pressure and renal function. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients who should not receive this medicine under Precautions for Use.) ○ Older adults: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In older adults, blood pressure should be monitored more closely and more frequently.
Child dose
○ Children: The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
Hanlim Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication helps patients with essential hypertension effectively control their blood pressure. If blood pressure control is insufficient when using escitalopram or olmesartan medoxomil alone, this treatment can be utilized to stably lower blood pressure. This leads to improved blood pressure management and helps reduce the risk of cardiovascular diseases. Therefore, it is actively used for the treatment of essential hypertension.

How to take

Adult dose

This medicine is administered as 1 tablet once daily with water, without regard to meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended to adjust the dose using the individual components (S-amlodipine (amlodipine) or olmesartan medoxomil). However, if blood pressure is not adequately controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 5/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into account. The recommended doses are as follows. - 2.5/20 mg: Administer to patients whose blood pressure is not adequately controlled with S-amlodipine 2.5 mg (amlodipine 5 mg) or olmesartan medoxomil 20 mg as monotherapy. - 5/20 mg: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg as monotherapy. - 2.5/40 mg: Administer to patients whose blood pressure is not adequately controlled with 2.5/20 mg. - 5/40 mg: Administer to patients whose blood pressure is not adequately controlled with 2.5/40 mg. ○ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily, and administration of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ○ Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics should be closely monitored for blood pressure and renal function. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients who should not receive this medicine under Precautions for Use.) ○ Older adults: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In older adults, blood pressure should be monitored more closely and more frequently.

Child dose

○ Children: The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Precautions

This medication can cause serious harm to the fetus and newborn during the second and third trimesters of pregnancy, so if pregnancy is confirmed, it should be discontinued immediately. Patients with allergies to this medication or similar drugs, those who are pregnant or breastfeeding, patients with severe liver disorders, aortic stenosis, biliary obstruction, renal dialysis, shock, specific diabetes patients, and patients with renal impairment should not take this medication. Patients with fluid or salt depletion, those at risk of rapid vascular expansion, severe obstructive coronary artery disease, congestive heart failure, impaired renal function, and those with decreased liver function should use this medication with caution and be closely monitored. While taking this medication, side effects such as dizziness, headache, hypotension, edema, dyspepsia, rash may occur, and if symptoms persist, consult a doctor. This medication is not a beta-blocker, hence beta-blockers should be gradually reduced to avoid risks related to sudden cessation. When taken with other medications that can affect blood pressure control, regular monitoring of blood pressure, renal function, and electrolyte levels is required, particularly because of the risk of elevated potassium levels. Taking this medication during pregnancy can cause serious side effects in the fetus, so it should not be used during pregnancy, and if planning to conceive, a doctor should be consulted. During breastfeeding, this medication may be transmitted through breast milk, so it is advisable to either discontinue breastfeeding or stop taking the drug. Safety and efficacy have not been established for patients under 18 years of age, so it is not recommended. Elderly patients may have reduced renal and liver function, therefore should start from a low dose and be cautious during administration. In cases of overdose, severe hypotension, vascular expansion, and rapid heart rate may occur, so immediate medical attention is required.

Side effects

Drug hypersensitivity, hyperkalemia, reduced libido, dizziness, headache, orthostatic hypotension, drowsiness, paresthesia, diminished perception, syncope, vertigo, palpitations, rapid pulse, hypotension, orthostatic hypotension, dyspnea, cough, nausea, vomiting, dyspepsia, diarrhea, constipation, dry mouth, upper abdominal pain, rash, urticaria, muscle tension, limb pain, back pain, frequent urination, erectile dysfunction, peripheral edema, edema, dependent edema, fatigue, asthenia, facial edema, decreased serum potassium, increased serum creatinine, increased serum uric acid, increased gamma-glutamyl transferase, decreased hemoglobin, decreased hematocrit, back pain, bronchitis, increased creatine phosphokinase, hematuria, hyperglycemia, hypertriglyceridemia, influenza-like symptoms, pharyngitis, rhinitis, sinusitis, asthenia, angioedema, chronic malabsorption - similar intestinal disease, intestinal vascular edema, rhabdomyolysis, acute renal failure, hair loss, pruritus, autoimmune hepatitis, flushing, fatigue, edema, palpitations, vertigo, headache, drowsiness, abdominal pain, nausea, gynecomastia, jaundice, elevated liver enzymes, leukopenia, thrombocytopenia, toxic epidermal necrolysis, hypotension, tachycardia, bradycardia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent air or moisture from entering, and it is important to maintain a storage temperature between 1 degree and 30 degrees Celsius. Proper storage can help maintain the drug's effectiveness over time.

Appearance and packaging

Appearance

White round film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.